Dani Castillo, Medical Oncologist and Researcher in COH, shared a post on X:
“The publication caught my attention because it cites our work, diagnostic challenges with PD-L1 and CLDN18.2 biomarkers. CLDN18.2 shows better baseline consistency but affected by tx changes, necessitating post- neoadjuvant reassessment.
PD-L1 often underestimated in biopsies, impacts pts selection for ICI. Accurate biomarker assessment is critical for effective treatment decisions.”
Other articles featuring Dani Castillo on OncoDaily.